CDKN2B and acute lymphoblastic leukemia: However, it is surprising that only one study has explored the outcome of CDKN2B inactivation by methylation or deletion in T-ALL patients [75], showing that patients with either biallelic deletion or a high level of methylation exhibit lower 3-year EFS and OS than those with monoallelic deletion or low levels of methylation (Table 4).